{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-22-000097","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2022-06-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.138918+00:00","generated_at":"2026-06-24T22:30:58.535926+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Ligand appoints Jason Haas to Board of Directors, effective June 29, 2022","bullets":["Jason Haas appointed to Board and Audit Committee; brings 30+ years healthcare investment banking experience.","Haas currently CFO of Syros Pharmaceuticals; previously Co-Head Americas Healthcare Banking at Barclays.","Received 1,750 RSUs and options for 5,907 shares at $88.52, vesting over three years.","Chairman Kozarich cites Haas' 10+ years as Ligand financial advisor; appointment ahead of OmniAb spin-off."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-22-000097","json":"https://secwatch.observer/filing/0000886163-22-000097.json","markdown":"https://secwatch.observer/filing/0000886163-22-000097.md","text":"https://secwatch.observer/filing/0000886163-22-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/0000886163-22-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/lgnd-20220629.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T22:30:58.535926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e1e2beb5b5","claim":"Jason Haas was appointed as Director at LIGAND PHARMACEUTICALS INC.","evidence_excerpt":"Effective as of June 29, 2022, the Board of Directors of Ligand Pharmaceuticals Incorporated (the “Company”) appointed Jason Haas to the Company’s Board of Directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616322000097/0000886163-22-000097-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}